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ABSTRACT: In a prospective case series of patients 
with Blau-Jabs syndrome (BJS) conducted in the 
Ophthalmology Department/Federal University of 
Sao Paulo, seven patients with clinical and oph-
thalmologic manifestations of the disease and a 
positive genetic test result for the presence of a mu-
tation in the CARD15/NOD2 gene were followed for 
a minimal period of 1 year. All patients had uveitis, 
five had nummular corneal subepithelial opacities, 
and four had multifocal choroiditis. Oral predniso-
lone was administered to all patients; inflamma-
tion was controlled in six patients with at least one 
immunosuppressive drug. Infliximab (Remicade; 
Janssen Pharmaceuticals, Beerse, Belgium) and 
etanercept (Enbrel; Amgen, Thousand Oaks, CA) 
were used to treat two cases refractory to the anti-
inflammatory drugs. A subconjunctival dexametha-
sone implant (Ozurdex; Allergan, Irvine, CA) and 
a periocular injection of triamcinolone were used 
in one case to achieve inflammation control. Six 
patients achieved a visual acuity of 20/25 or bet-
ter. The authors conclude that periocular treatment 
with steroid injections might be effective adjuvant 
therapy to control ocular inflammation.
[Ophthalmic Surg Lasers Imaging Retina. 2018;49:70-75.]
INTRODUCTION
Blau-Jabs syndrome (BJS), first described simultane-
ously by Blau and Jabs in 1985, is an autosomal domi-
nant chronic inflammatory syndrome defined by early 
onset of noncaseating granulomatous dermatitis, arthri-
tis, and uveitis.1,2 The disease is rare, with fewer than 
200 cases reported by 2015, most of them with onset in 
white patients younger than 4 years of age.3-5 The main 
differential diagnosis is sarcoidosis.4,5 BJS is distin-
guished from sarcoidosis by the absence of pulmonary 
involvement and adenopathies, the arthritis pattern, 
and familial inheritance6 related to the CARD15 (cas-
pase activation and recruitment domain [CARD] family, 
member 15)/NOD2 (nucleotide-binding oligomeriza-
tion domain-containing protein 2) gene on chromosome 
16q12, identified in 2001.4,5,7 This gene also is involved 
in Crohn’s disease.7
Anterior, posterior, and diffuse uveitis, and corne-
al opacities might occur.7-9 Ocular involvement is de-
scribed as the most relevant morbidity of BJS.3 Uveitis 
generally is later and bilateral and might lead to low vi-
sual acuity (VA) in up to 46% of cases.7,10-12 Other ocu-
lar lesions are conjunctival nodules and multifocal cho-
roidal and granulomatous optic disc lesions.10,12 Most 
cases are treated with oral steroids;5,13 many also need 
immunosuppressive agents. Recurrences are common.7 
Biologic anti-cytokine agents have been suggested to be 
promising treatments in refractory cases.3,14
The goals of the current study were to increase the 
information in the literature about the demographic, 
clinical ophthalmological and systemic findings, and 
the beneficial treatments for this rare disease.
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PATIENTS AND METHODS
In a prospective study, seven patients diagnosed 
with BJS in a tertiary care ophthalmology depart-
ment of the Federal University of São Paulo, Brazil, 
from 2014 to 2015 were consecutively selected and 
included. Investigational review board approval 
was obtained for this study. The diagnostic crite-
ria were the clinical and ophthalmologic manifes-
tations and a mutation in the CARD15/NOD2 gene 
identified by genetic testing. All patients had a fol-
low-up of at least 1 year and underwent systemic 
and ophthalmologic examinations and genetics 
evaluations.
RESULTS
From 2014 to 2015, seven patients with BJS were 
diagnosed, all of whom had a positive genetic test 
for BJS (presence of a CARD15/NOD2 mutation). 
Five (71%) patients were female, and the average 
age was 18.5 years (range: 10 years to 41 years). All 
patients had granulomatous uveitis, five had pan-
uveitis, and two had anterior uveitis. Five (71%) 
patients had nummular corneal subepithelial opac-
ities (Figure 1) and four (57%) had multifocal cho-
roiditis. Table 1 shows the clinical presentations, 
treatment, and complications.
All patients presented with arthritis; only one 
did not have a skin rash. Two (29%) patients also 
had chronic fever and one (14%) had a history of 
diarrhea. All patients were treated with oral predni-
sone, six (86%) used at least one immunosuppres-
sive drug to control inflammation — specifically, 
methotrexate (83%) and cyclosporine (40%). In two 
refractory cases, biologic drugs were introduced — 
infliximab (Remicade; Janssen Pharmaceuticals, 
Beerse, Belgium) (Case 1) and etanercept (Enbrel; 
Amgen, Thousand Oaks, CA) (Case 5). In Case 1, 
despite treatment with steroid pulse therapy and 
immunosuppressive agents, the patient presented 
with refractory anterior uveitis (Figures 2A and 
Figure 1. Case 3. Anterior biomicroscopy image of an eye with uveitis in Blau-Jabs syndrome. Nummular corneal opacities and posterior 
synechiae are seen.
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2B). Treatment with a subconjunctival dexametha-
sone implant (Ozurdex; Allergan, Irvine, CA) in the 
left eye and a periocular triamcinolone injection in 
the right eye was added to control the inflammation 
(Figure 2C). The ocular hypertension that devel-
oped after the subconjunctival implant in the left 
eye was controlled with topical timolol 0.5%. No 
other patient developed ocular hypertension dur-
ing the study period.
The most common treatment-related compli-
cation was posterior synechiae in 86%, followed 
by posterior subcapsular cataract (29%), macular 
edema (29%), and corneal band keratopathy (14%). 
One patient did not have any complications. After 
treatment, six (86%) patients had a VA of 20/25 or 
better. No surgical treatment for cataract and band 
keratopathy was required at this moment. The low 
VA persisted in one patient (Case 4) likely because 
of dense bilateral corneal band keratopathy.
DISCUSSION
BJS is an autosomal dominant disease caused by 
a mutation in the caspase recruitment domain gene 
CARD15/NOD2.3,12 The disease classically presents 
in early childhood and is characterized by granulo-
matous dermatitis, arthritis, and uveitis.4,13,15 The 
current patients were older than those reported in 
the literature probably due to the difficulty in di-
agnosing the disease, both because of its rarity and 
the need for confirmatory genetic testing. The liter-
ature states that uveitis generally is present in 60% 
to 80% of patients 2 years to 4 years of age.13 All of 
the current patients had uveitis, possibly because 
the study was performed in a tertiary ophthalmo-
logical center. 
Rash, usually the first sign to appear in BJS,13,15 
most often is an erythematous maculo/micropapu-
lar fine scaly rash on the trunk and extremities.5,13,16 
The arthritis in BJS manifests as polyarticular syno-
vitis and tenosynovitis, usually in the wrists, knees, 
ankles, and proximal interphalangeal joints (PIP) of 
the hands.4,5,13 All current patients presented with 
arthritis and only one did not have the skin rash. A 
characteristic manifestation (ie, camptodactyly) is 
contracture of the PIP joints relatively early in the 
disease course and out of proportion to the degree 
of synovitis.5,13,15 Other systemic manifestations 
seen in our series were chronic fever and diarrhea. 
Ocular involvement occurs in 80% to 85% of pa-
tients and is typically a chronic bilateral granulo-
matous iridocyclitis with posterior uveitis.5,13 The 
ocular inflammation might evolve to severe panu-
veitis with multifocal choroiditis.5,13 In the current 
series, all patients had granulomatous uveitis, most 
with panuveitis, but some with anterior uveitis and 
four with multifocal choroiditis. 
Corneal opacities were first described by Cha-
darévian et al. in 1993. Since then, other authors 
have described the same alterations as small, eva-
nescent, ovoid corneal subepithelial, and stromal 
opacities.7,9 Corneal opacities have been described 
in other CARD15/NOD2-associated diseases such as 
Crohn’s disease, but they are usually epithelial and 
subepithelial and located in the peripheral and jux-
talimbal cornea and have a partial response to cor-
ticoid therapy.17 In the current patients, 71% had 
nummular opacities that persisted and increased in 
number in proportion to the degree of inflamma-
tion. Thus, they helped in the diagnosis of disease 
activity and in monitoring the treatment response. 
Other possible ocular findings are: epiretinal 
membranes, granulomatous discs, papilledema, 
ischemic optic neuropathy, retinal vasculitis, pro-
gressive subretinal fibrosis, and fourth nerve pal-
sy.2,3,13,18 Ocular involvement in BJS has been report-
ed to complicate the disease in more than a third of 
Figure 2. Case 1. Anterior biomicroscopy image of an eye with uveitis in Blau-Jabs syndrome. (A) Posterior synechiae with a pupillary 
membrane. (B) Granulomatous conjunctivitis with hyperemia, nodules, and posterior synechiae. (C) A dexamethasone subconjunctival 
implant helped control the inflammatory activity.
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cases, most often with posterior synechiae, band kera-
topathy, cataract, glaucoma, cystoid macular edema, 
optic atrophy, and retinal detachment.1-3,10-13,18 In a 
study of 22 patients, 16% presented with blindness 
and 11% with moderate visual impairment.13 The 
current results agreed with those reported in the lit-
erature, with the main complications being posterior 
synechiae, posterior subcapsular cataracts, macular 
edema, and corneal band keratopathy. 
Despite the characteristic clinical findings, the 
final diagnosis is based on the results of genetic 
testing. BJS is associated with different CARD15/
NOD2 mutations on chromosome16q12.4,13 The ef-
fects of the CARD15/NOD2 mutations in BJS are 
not totally understood; some authors believe that 
mycobacterial components might trigger granulo-
matous autoinflammation.5 
Although there is no consensus about the opti-
mal treatment for patients with BJS, they require 
continuous follow-up.5,13 More than two-thirds of 
patients with BJS received medical therapy, often 
high-dose steroids, especially in the acute stag-
TABLE 1
Clinical Ocular and Systemic Presentations and Complications
Case Gender Age 
(Years)
Ocular Findings Systemic 
Findings
Treatment Complications















infliximab + periocular 
triamcinolone aceton-
ide OD and subcon-
junctival dexametha-
sone implant OS
Side effects of 
mycophenolate, 
posterior subcapsu-




2 Female 12 Granulomatous 
panuveitis, panuve-








3 Male 10 Granulomatous 










4 Female 28 Recurrent granuloma-










5 Female 21 Recurrent granuloma-










6 Female 41 Recurrent granuloma-





Oral prednisone Posterior subcapsular 
cataract, poste-
rior synechiae and 
macular edema UO
7 Female 10 Anterior granuloma-




Arthritis Oral prednisone, 
methotrexate
Posterior synechiae
OU = both eyes; OS = left eye; OD = right eye
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es.4,5,13 Most patients also are treated with the same 
immunosuppressive drugs used for juvenile idio-
pathic arthritis and chronic uveitis (methotrexate, 
azathioprine [Azasan; Salix, Raleigh, NC], or my-
cophenolate mofetil [CellCept; Genentech, South 
San Francisco, CA]), since long-term use of corti-
costeroids may cause serious adverse effects.3,5,12,19 
Marked results have been achieved with canakinum-
ab (an anti-interleukin [IL]-1 monoclonal antibody) 
for this disease, and variable results with anakinra 
(IL-1 receptor antagonist).20,21
In the current case series, all patients were 
treated with oral prednisone and most needed at 
least one immunosuppressive drug to control ocu-
lar inflammation, especially methotrexate and cy-
closporine. Thalidomide seems to be a promising 
agent for reducing granulomatous inflammation by 
suppressing nuclear factor kappaB activation and 
interference with the proliferation and differentia-
tion of monocytes.3,15 Anti-tumor necrosis factor-al-
pha agents, such as adalimumab (Humira; AbbVie, 
North Chicago, IL) and infliximab, have achieved 
good results in some patients.5 However, in a study 
of 22 patients with BJS, most presented with persis-
tent active disease.13 The results vary with immu-
nosuppressive agents and tumor necrosis factor in-
hibitors, particularly regarding ocular morbidity,12 
and we used infliximab and etanercept in two re-
fractory cases without good responses. Uveitis can 
be treated with steroid eye drops associated with 
systemic therapy.4 Close monitoring is important to 
avoid complications and decreased quality of life, 
since almost half of patients with BJS reported a 
moderate-to-severe disease effect on their lives and 
moderate-to-severe pain.13
We believe that Case 1 is the first published BJS 
case treated with periocular corticosteroids (peri-
ocular injection and subconjunctival implant) that 
had a good response and no substantial compli-
cations. We believe this kind of treatment can be 
helpful in patients who do not tolerate high doses 
of systemic steroids or have important immuno-
suppressive therapy side effects. In our case series, 
just one case did not recover good VA after a 1-year 
follow-up due to dense bilateral corneal band kera-
topathy.
Much still needs to be ascertained about BJS, 
such as the risk factors for severe ocular involve-
ment and the correlations between the clinical 
manifestations and genetic mutations. The current 
study described the demographic, clinical ophthal-
mologic, and systemic findings and treatments in 
seven patients with BJS. Periocular treatment with 
steroid injections may be an adjuvant therapy for 
ocular inflammation. This syndrome may be misdi-
agnosed due to its rarity and similar manifestations 
to other diseases. Thus, ophthalmologist must be 
aware of the BJS manifestations, think about this 
diagnosis, and order a genetic test to confirm it.
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